December 2012

Covidien buys PAD device maker ()
Eliquis wins regulatory approvals in U.S., Japan ()
FDA approves Juxtapid for rare cholesterol disease ()
MRI software helps to detect damage from stroke ()
FDA clears Avinger's CTO catheter ()
Merck’s combo drug fails to reduce cardiac risks ()
Twelve in 2012 from Cardiovascular Business ()
FDA: Stop using Pradaxa in patients with mechanical heart valves ()
Pediatric survival of in-hospital cardiac arrest improving, but remains low ()
Amgen settles civil, criminal cases for off-label marketing for $762M ()
Readmissions & reassessing PCI practices ()
More hospitalizations: Secret to improving HF mortality? ()
AstraZeneca keeps dibs on Crestor ()
Clopidogrel fails to reduce mortality risk in most PCI patients ()
VA offers model for achieving quality, efficiencies ()
CardioSCORE’s blood test earns CE Mark ()
Guidelines for STEMI care emphasize treatment urgency ()
Renal denervation results remain positive ()
Policy-level interventions drive BP drug adherence across ethnic groups ()
Nonprofit hospitals in 2013: Stable, frugal, fewer ()
Nonteaching GWTG hospitals close quality gap over time ()
Cardiology near top for accepting Medicare ()
Birth of new subspecialty: adult congenital heart disease ()
Canada OKs Covidien's stroke revascularization device ()
Registries & Randomization ()
Newest Frontier in Cardiac Care: Kidneys ()
EHRs & CVD: The Good, the Bad & the Future ()
FFR is Integral in PinnacleHealth’s Reform Strategy ()
Boehringer pulls plug on dabigatran’s heart valve trial ()
PCI boundaries & barriers ()
Medicines, Bristol-Myers ink $115M deal for surgical hemostat ()
Rivaroxaban scores points for lower costs, hospital stays ()
FDA: Smoking cessation drug increases CV events, a little ()
Ballooning Inpatient AF Costs: A $26 Billion Conundrum ()
C-suite CV Executives Prepare for an Evolving Landscape ()
PET MPI stratifies risk, but clinical relevance uncertain ()
Service Lines: Getting It Straight Under Reform ()
Thriving as a Cardiologist in the Post-reform Era ()
Georgia on my mind: New Hospital Development Model Emerges ()
Thoracic Surgery: New Alliance Under ICD-10 ()
Study sees benefits in direct-to-consumer statin ads ()
Cerebral angioplasty, stenting show positive outcomes ()
Japan clears HeartMate II as bridge therapy ()
Cytoreductive drugs lower CV risk in those with rare, bone marrow disease ()
Is it time to re-examine appropriate use terminology? ()
Excela Health coughs up nearly $2M to settle stenting case ()
Dutch ischemic stroke mortality drops, but incidence holds steady ()
Heart surgeon accidently infects 5 patients ()
Two doses of apixaban cut VTE recurrence ()
Diuretic combo benefits obese hypertensive patients, maybe ()
Pumps & PMAs: Is FDA overstepping its bounds on advising panels? ()
Nationwide study gives tobacco ban advocates a smoking gun ()
FTC reopens CV services competition in Reno ()
Canada gives apixaban go-ahead for AF patients ()
FDA makes labeling changes to heparin ()
Beyond a fax faux pas ()
Low BMI emerges as long-term risk of death, stroke post-TAVI ()
Just the fax: Heart center sues over unsolicited invites ()
Hub-and-spoke telestroke network cost-effective ()
Coating on aspirin may mask drug’s benefits ()
Distrust may compel patients to accept lower compensation ()
Model helps docs choose between clopidogrel and prasugrel ()
FDA yanks anti-nausea drug due to arrhythmia risks ()
Volcano delves into PE market with nearly $40M buy of Crux ()
Readmissions penalties seen as flawed ()
SCAI consensus statement advises more consideration before ad hoc PCI ()
Baxter expands dialysis line with $4B purchase of Gambro ()
Florida health system garners ACE laurels ()
Warfarin risk highest in first 30 days of therapy ()
Score helps docs assess CAS risk in high-risk patients ()
Medtronic’s Q2 earnings drop 26% ()